AbbVie sues BeiGene over Imbruvica patent
On June 15, AbbVie filed a lawsuit against BeiGene, claiming that BeiGene’s Brukinsa has infringed a patent on its blood cancer drug Imbruvica. The disputed patent, which relates to the "use of BTK inhibitors", was issued on June 13, just two days before AbbVie lodged the suit.